Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...

Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!

Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s ...

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.

Bambusa Therapeutics raises $90M Series A for bispecific antibodies, led by RA Capital. Founded by BioNTech veterans, plans ...

Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan ...

David Schenkein will step down from Agios Phar­ma­ceu­ti­cals ’ board of di­rec­tors at the end of the month “to de­vote more ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

Corbus' CRB-701 shows 23% response rate in early cancer trial, but shares fall after some patients with prior Padcev ...

Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 ...

A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that ...